TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA) announced that its Compensation Committee has approved inducement grants of restricted stock units (RSUs) to seven new employees. The grants, totaling 4,000 shares of common stock, were issued on January 21, 2025, under Nasdaq Rule 5635(c)(4). These RSUs will vest in equal annual installments over four years, contingent upon continued employment with the company. The grants were made as part of the employees' compensation packages and served as inducements for their acceptance of employment with TELA Bio, a commercial-stage medical technology company specializing in soft-tissue reconstruction solutions.
TELA Bio (NASDAQ: TELA) ha annunciato che il suo Comitato per la Compensazione ha approvato l’assegnazione di unità di azioni vincolate (RSU) a sette nuovi dipendenti. Le assegnazioni, per un totale di 4.000 azioni ordinarie, sono state emesse il 21 gennaio 2025, in conformità con la Regola 5635(c)(4) di Nasdaq. Queste RSU matureranno in rate annuali uguali nel corso di quattro anni, a condizione che i dipendenti continuino a lavorare con l'azienda. Le assegnazioni sono state effettuate come parte dei pacchetti di compensazione dei dipendenti e hanno rappresentato incentivo per l'accettazione dell'impiego con TELA Bio, un'azienda di tecnologia medica in fase commerciale specializzata in soluzioni per la ricostruzione dei tessuti molli.
TELA Bio (NASDAQ: TELA) anunció que su Comité de Compensación ha aprobado la concesión de unidades de acciones restringidas (RSUs) a siete nuevos empleados. Las concesiones, que suman 4,000 acciones comunes, se emitieron el 21 de enero de 2025, de acuerdo con la Regla 5635(c)(4) de Nasdaq. Estas RSUs se consolidarán en cuotas anuales iguales durante cuatro años, bajo la condición de que los empleados continúen en la empresa. Las concesiones se realizaron como parte de los paquetes de compensación para los empleados y sirvieron como incentivos para su aceptación del empleo en TELA Bio, una empresa de tecnología médica en etapa comercial especializada en soluciones de reconstrucción de tejidos blandos.
TELA Bio (NASDAQ: TELA)는 보상위원회가 7명의 신입 직원에게 제한 주식 단위(RSU)를 부여하기로 승인했다고 발표했습니다. 이 보상은 총 4,000주로, 2025년 1월 21일에 발행되었으며, 나스닥 규정 5635(c)(4)에 따라 이루어졌습니다. 이 RSU는 4년 동안 매년 동등한 비율로 발생하며, 직원이 회사에 계속 재직할 경우에만 유효합니다. 이러한 보상은 직원의 보상 패키지의 일환으로 제공되었으며, TELA Bio에 입사를 수락하기 위한 유인으로 작용했습니다. TELA Bio는 연부조직 복원 솔루션을 전문으로 하는 상업 단계의 의료 기술 회사입니다.
TELA Bio (NASDAQ: TELA) a annoncé que son Comité de rémunération a approuvé l'octroi d'unités d'actions restreintes (RSU) à sept nouveaux employés. Les octrois, totalisant 4 000 actions ordinaires, ont été émis le 21 janvier 2025, conformément à la règle 5635(c)(4) de Nasdaq. Ces RSU seront acquises par tranches annuelles égales sur quatre ans, sous réserve d'un emploi continu au sein de l'entreprise. Les octrois faisaient partie des packages de rémunération des employés et ont servi d'incitatifs à leur acceptation de l'emploi chez TELA Bio, une entreprise de technologie médicale en phase commerciale spécialisée dans les solutions de reconstruction des tissus mous.
TELA Bio (NASDAQ: TELA) hat bekannt gegeben, dass sein Vergütungsausschuss die Gewährung von beschränkten Aktieneinheiten (RSUs) an sieben neue Mitarbeiter genehmigt hat. Die Gewährungen, insgesamt 4.000 Aktien, wurden am 21. Januar 2025 gemäß der Nasdaq-Regel 5635(c)(4) ausgegeben. Diese RSUs werden über einen Zeitraum von vier Jahren in gleichmäßigen jährlichen Raten fällig, vorausgesetzt, die Mitarbeiter bleiben weiterhin im Unternehmen tätig. Die Gewährungen wurden als Teil der Vergütungspakete für die Mitarbeiter vorgenommen und dienten als Anreiz für die Annahme der Beschäftigung bei TELA Bio, einem Unternehmen der Medizintechnologie in der kommerziellen Phase, das sich auf Lösungen zur Rekonstruktion von Weichgewebe spezialisiert hat.
- Successful attraction of new talent with equity-based compensation
- Structured vesting schedule promotes long-term employee retention
- Potential dilution of existing shareholders through new stock units issuance
MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
How many shares of restricted stock units did TELA Bio grant on January 21, 2025?
What is the vesting schedule for TELA Bio's January 2025 inducement grants?
Why did TELA Bio issue these restricted stock units in January 2025?
Under which Nasdaq rule were TELA Bio's January 2025 inducement grants issued?
